Drug Profile
Research programme: autoimmune and inflammation therapeutics - Zymeworks
Latest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator Zymeworks
- Class Anti-inflammatories; Antibodies; Proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for research development in Autoimmune-disorders in Canada (Parenteral)
- 28 Oct 2020 No recent reports of development identified for research development in Inflammation in Canada (Parenteral)
- 19 Sep 2016 Early research in Autoimmune disorders in Canada (Parenteral)